Reaction
Dacryostenosis Acquired reporting signals
As of the last recalculation, Dacryostenosis Acquired appears in 1,280 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is DOCETAXEL ANHYDROUS (PRR 73.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Docetaxel Anhydrous | 246 | 73.2 | 73.5 |
| Docetaxel | 246 | 73.2 | 73.5 |
| Pertuzumab | 77 | 48.9 | 49.1 |
| Lifitegrast | 35 | 35.8 | 35.9 |
| Trastuzumab | 105 | 27.0 | 27.0 |
| Carboxymethylcellulose Sodium | 11 | 19.2 | 19.2 |
| Ado-Trastuzumab Emtansine | 7 | 13.6 | 13.6 |
| Carboplatin | 79 | 10.7 | 10.7 |
| Norepinephrine | 7 | 10.7 | 10.7 |
| Dorzolamide Hydrochloride And Timolol Maleate | 5 | 10.3 | 10.3 |
| Brinzolamide | 5 | 9.4 | 9.4 |
| Brimonidine Tartrate | 10 | 9.2 | 9.2 |
| Norepinephrine Bitartrate | 8 | 9.1 | 9.1 |
| Cenegermin-Bkbj | 6 | 8.1 | 8.1 |
| Pemetrexed | 10 | 7.6 | 7.6 |
| Travoprost | 4 | 7.5 | 7.5 |
| Bimatoprost | 13 | 7.4 | 7.4 |
| Pemetrexed Disodium | 13 | 5.6 | 5.6 |
| Pegfilgrastim | 27 | 4.5 | 4.5 |
| Dupilumab | 62 | 2.1 | 2.1 |